date:Mar 04, 2014
euroBioPharm in the development and validation of its product candidates, approximately US$5 million to finance the start-up and ramp-up of its new production facility, approximately US$2 million to maintain, manage and develop its intellectual property portfolio and to protect it against infringement by third parties, and the balance for general corporate and other working capital purposes.
The closing of the offering is expected to occur on or about March 5, 2014.
Neptune continues to recove